Machine Learning Models for Blood Glucose Level Prediction
|
|
- Sherman Singleton
- 5 years ago
- Views:
Transcription
1 Machine Learning Models for Blood Glucose Level Prediction Sadegh M. Hui Shen Cindy Marling Matt Wiley Franck Schwarz Nigel Struble Jay Shubrook Lijie Xia Razvan Bunescu School of EECS & Diabetes Institute, Ohio University Talk at University of Akron, Oct 20, 2017 Kevin Plis
2 Management of Type I Diabetes Approximately 20 million people have Type 1 Diabetes: In type 1 diabetes, the pancreas produces no insulin. Patients depend upon external supplies of insulin, via injections or insulin pumps. Diabetes can not be cured, but it can be treated and managed: To delay or prevent long-term complications, patients try to keep Blood Glucose Levels (BGL) as close to normal as possible. Good blood glucose control requires: 1. Monitoring BG levels. 2. Corrective steps to avoid hyper- and hypo-glycemia. 2
3 Chronic Complications vs. Blood Glucose Control RISK Microalbuminuria Mild Retinopathy Mild Neuropathy Albuminuria Macular Edema Proliferative Retinopathy Periodontal Disease Impotence Gastroparesis Depression Foot Ulcers Angina Heart Attack Coronary Bypass Surgery Stroke Kidney Transplant Dialysis Blindness Amputation Good CONTROL Poor 3
4 Management of Type I Diabetes Blood glucose levels are monitored using: Glucometers (fingerstick measurements). Continuous Glucose Measurement Systems (CGMS): CGM sensor. Insulin pump. 4
5 Continuous Glucose Monitoring (CGM) in Insulin Pump Therapy Systems CGM Sensor: interstitial BGL. every 5 minutes. Insulin Pump delivers insulin through boluses and basal rate: 5
6 Achieving Good Blood Glucose Control Patients must continually monitor their blood glucose levels and adjust insulin doses, striving to keep blood glucose levels as close to normal as possible: Requires significant effort from patients and doctors. Try to avoid especially: Hypoglycemia Hyperglycemia Excessive Glycemice Variability forecasting of blood glucose levels detection of glycemic variability 6
7 Outline 1. BGL prediction using manually engineered physiological models: Physiological Equations + Kalman filtering + SVR. 2. BGL prediction using trained physiological models. RNNs with LSTM units. 3. Attention models for time series prediction. 4. From physiological models to automated BGL control. 7
8 Automatic BGL Prediction Develop time series forecasting models that predict BGL 30 or 60 minutes into the future: Accurate predictions up to 60m in advance would allow plenty of time to take preventive action, to avoid hypo- or hyper-glycemia. Inputs for the prediction model: Previous blood glucose measurements taken at 5-minute intervals through a CGM system. Daily event data: Insulin dosages, recorded in the CGM device. Life events, collected through a smartphone interface. 8
9 Input: Life Events Developed a smartphone interface to collect relevant life events: Meals (carb amounts, glycemic index). Sleep (start, end). Work (start, end). Exercise (intensity, start, duration). Hypoglycemic event. Health events (stress, depression,...). Other events. Designed to encourage entering events immediately before/after they happen: to minimize incorrect/incomplete data. 9
10 10
11 First Evaluation Dataset Total of 1,400 days worth of clinical patient data: CGMS + insulin + life events. Human performance on the task of BGL prediction: Asked 3 diabetes experts to manually label an evaluation dataset with their 30/60 min predictions: 200 timestamps, coming from 5 patients with T1D. 40 points per patient. Manually selected to reflect a diverse set of situations. Built a GUI to facilitate navigating the data and labeling. 11
12 12
13 13
14 Physician Performance Compared the 3 physicians against 2 baselines: t 0 predicts that future BGL is the same as current BGL. Auto-Regressive Integrated Moving Averages (ARIMA), trained on past BGL data. Evaluation measures: Root Mean Square Error (RMSE). Total cost of ternary classification: Future BGL is Same (S), Lower (L), Higher (H) as current BGL. Same means within 5 (10) mg/dl for 30 (60) min prediction. cost(l, S) = cost (H, S) = 1; cost(l, H) = 2. 14
15 Physician Performance Physicians, who use daily event data, outperform ARIMA. Physicians regularly refer to daily events: Timing of meal events and boluses, carb amouns, bolus types. 15
16 Physician Performance Physicians, who use daily event data, outperform ARIMA. Physicians regularly refer to daily events: Timing of meal events and boluses, carb amouns, bolus types. Use daily events to extract features for automatic BGL prediction. 16
17 Physiological Modeling of BG Dynamics Use equations from literature [6, 7, 8, 9] to model dynamics of variables that are relevant to BG behavior: Almost identical equations (based on the same data). Characterize the overall dynamics into 3 compartments: Meal absorption dynamics. Insulin dynamics. Glucose dynamics. Changed some of the equations and their parameters to better match published data and feedback from our doctors. 17
18 A Physiological Model of BG Dynamics A continuous dynamical model that is described by: 1) The input variables U. 2) The state variables X. 3) The state transition function f that computes the next state given the current state and input i.e. X t+1 = f(x t,u t ). 1) The vector of input variables U contains: U C (t), the carbohydrate intake measured in grams (g). U I (t), the amount of insulin measured in insulin units (U): Computed from bolus events and basal rate data. 18
19 A Physiological Model of BG Dynamics 1) The state variables H are organized according to the 3 compartments: 1) Meal Absorption Dynamics: C g1 (t) = carbohydrate consumption (g). C g2 (t) = carbohydrate digestion (g). 2) Insulin Dynamics: I S (t) = subcutaneous insulin (µu). I m (t) = insulin mass (µu). I(t) = level of active plasma insulin (µu/ml). 3) Glucose Dynamics: G m (t) = blood glucose mass (mg). G(t) = blood glucose concentration (mg). 19
20 A Physiological Model of BG Dynamics 2) The state transition function f captures dependencies among variables in H and U at consecutive time steps: 20
21 A Physiological Model of BG Dynamics 2) The state transition function f captures dependencies among variables in H and U at consecutive time steps: 21
22 A Physiological Model of BG Dynamics 2) The state transition function f captures dependencies among variables in H and U at consecutive time steps: 22
23 Glucose Dynamics: Insulin Dependent Utilization 23
24 Glucose Dynamics: Insulin Dependent Utilization G m (t+1) = G m (t) Δ dep Δ ind Δ clr Δ dep + Δ abs + Δ egp Δ dep = α 1 I(t) [G(t) + α 2 ] 24
25 Physiological Model Equations 25
26 A Physiological Model of BG Dynamics The state transition equations were used in an Extended Kalman Filter (EKF) model: Run a state prediction step every 1 minute. Run a correction step every 5 minutes. The EKF model itself can be used to make 30 or 60 minute predictions: Performance is lower even than the t 0 baseline. Could improve by tunning the α parameters for each patient: Time consuming, unfeasible due to large number of params. Difficult to incorporate other types of life events in the model. 26
27 A Support Vector Regression (SVR) Model with Physiological Features The state vector H(t) computed by the physiological model is H(t) = [C g1 (t), C g2 (t), I S (t), I m (t), I(t), G m (t), G(t)]: Run the EKF model up to time t 0, with a correction step every 5 minutes => H(t 0 ). Run the EKF model in prediction mode for 60 more minutes => H(t ) and H(t ). Create the following features for the SVR model: All predicted state variables in H(t ) and H(t ). The difference vectors H(t 0 ) H(t ) and H(t 0 ) H(t ). 12 features delta i = BG(t 0 ) BG(t 0 5i). Optionally, train ARIMA on 4 days before t 0, and use the 12 predictions in the one hour after t 0 as features
28 SVR Evaluation Train SVR on the week of data preceding each test point t 0 : Use a Gaussian kernel: Tune parameters γ, ε, and C using grid search on the week preceding the training week. If not enough tunning examples, use generic parameters tuned on another patient. Compare the best doctor performance with: ARIMA and the t 0 baselines. SVR model using physiological features, with (SVRφ+A) and without (SVRφ) ARIMA features. A previous SVR system (SVRπ+A) that uses CGM data, ARIMA, and an ad-hoc implementation of daily event features. 28
29 Experimental Results on BGL Prediction 29
30 Experimental Results on BGL Prediction Both SVRφ systems outperform the 3 diabetes experts! 30
31 Outline 1. BGL prediction using manually engineered physiological models: Physiological Equations + Kalman filtering + SVR. 2. BGL prediction using trained physiological models. RNNs with LSTM units. 3. Attention models for time series prediction. 4. From physiological models to automated BGL control. 31
32 BGL Prediction: What next? We used as input only the history of BG levels, insulin and carbohydrates: Manually engineered physiological model equations. There are many other factors that can impact BG levels: Exercise, Stress, Depression, Medication, How do we measure the relevant factors? 2. How do we use more factors in the physiological model? 32
33 1. How to Measure? Exercise / effort has a significant impact on BGL behavior. Patients have been telling us when and how much they exercise: Unfeasible in practice. Very coarse-grained data. Better use sensors to acquire measurements of relevant physiological parameters: Skin conductivity. Heart rate. 3D acceleration. Skin and Air Temperature. 33
34 2. How to Model? Manually re-engineer the physiological model equations to incorporate exercise: Cognitively demanding, because complex problem => a complex model is required. Time consuming: the equations have to be re-engineered every time we add another physiological parameter. Automatically learn physiological models of BG behavior: Deep Learning mantra(s): The learning algorithm is simple: Fits on 1 slide (a bit more complicated in practice ) The learned behavior is complex: The complexity comes from the training data! 34
35 Manually Engineered State Transition Model G G State transition equations H t+1 = f(h t,u t+1 ) are recursive: Use RNNs to learn them! Neural networks are Universal Approximators 35
36 Equivalent Recurrent Neural Network t U t+1 H t G t H t+1 t+1 G t+1 G t+30, G t+60 36
37 Recurrent Neural Networks (RNN) U t = [BGL t-1, Insulin t, Carbs t, ] G t = BGL t G 1 G 2 G 2 G t G t+1 f(h 0,U 1 ) f(h 1,U 2 ) f(h t-1,u t ) f(h t,u t+1 ) H 1 H 2 H 2 H t H t+1 U 1 U 2 U 2 U t U t+1
38 RNN Training Procedure Use long short-term memory (LSTM) units: Experiments showed better performance than vanilla RNNs. The BG levels are scaled by 0.01, whereas all other input values are normalized in [0, 1]. Target is relative difference BG(t 0 +60) BG(t 0 ). Missing BG levels are linearly interpolated. [Mirshekarian et al., EMBC 17] Interpolated BG levels are never used as prediction targets during training. Backpropagation through time (BPTT) is done for 12 hours. This is also how long in the past the LSTM network will be unrolled at test time. The MSE objective is minimized using RMSProp with a batch of
39 Dealing with Cold Start Examples The number of training examples varies from only a few days for the first test points to more than two months for the last test points. To address the insufficient number of training examples for the early test points, training is done in two steps: Pre-training. Fine-tuning. 39
40 Pre-training An LSTM model is pretrained on 3 development patients + the other 4 test patients: Learning rate of Early stopping on 2 other development patients. The weights are initialized using the Glorot uniform scheme. The pretrained weights are used to initialize the parameters only for the first test example in each patient. For each subsequent test example, the weights are initialized with those learned for the previous test example. 40
41 Fine-tuning After pre-training, a separate model is fine-tuned on the BG level history for each test point. Use annealing for the learning rate. The number of epochs increases linearly with the number of training examples available in the BGL history for each test point: For test examples early in the sequence, the initial pre-trained weights will not be changed much. For a test example late in the sequence of BG levels, the initial weights could be changed more substantially, based on a much larger number of patient specific training examples. 41
42 Experimental Evaluation Setting The original dataset of 200 points contains 67 points that have what-if events, i.e. meals or carbs in the prediction horizon [t 0, t ]: Both the physiological model and the doctors had access to these events. Idea was to evaluate performance for what-if predictions. The RNN cannot use the what-if events... unless it is used to initialize a second RNN running from t 0 to t that does not see BG levels (future work!). We evaluated both the SVR+φ and the RNN on the 200 points, but ignoring the what-if events. 42
43 Trained Physiological Models vs. Manually Engineered Physiological Models RMSE on the 200 test points, ignore what-if events: TPM = Trained Physiological Model (RNN). EPM = Enginered Physiological Model (SVR+ARIMA+PM+Kalman). Horizon t 0 ARIMA EPM TPM 30 min min when trained on only previous 2 weeks, decreased to 37.4 RMSE on the 129 points without what-if events: Horizon t 0 ARIMA EPM TPM 60 min
44 Experimental Results 1. The trained Recurrent Neural Networks (LSTMs) are competitive with the manually engineered Physiological Models. Both are competitive with and often outperform expert physicians. 2. RNN model is more flexible, it can incorporate arbitrary physiological measurements: Do they help in practice? 44
45 45
46 Preliminary results Experimented with data from one patient, wearing a Basis band: LSTM: the original RNN system, trained on BGL, insulin and carbs. Tuned layer size 20, dropout rate 0.1, early stopping. Used only points with no what-if events in prediction horizon. LSTM+band: trained on BGL, insulin, carbs + heart rate, GSR, temperature. Ran 12 rounds, from different random initializations: LSTM: mean (std 0.35) LSTM+band: mean (std 0.22) 46
47 Outline 1. BGL prediction using manually engineered physiological models: Physiological Equations + Kalman filtering + SVR. 2. BGL prediction using trained physiological models. RNNs with LSTM units. 3. Attention models for time series prediction. 4. From physiological models to automated BGL control. 47
48 Memory-Augmented BGL Prediction History repeats itself: A patient may go through the same situation multiple times: Currently BGL around 100, ate 100 carbs 30 min ago, bolused 2mg 35 min ago. Similar situations expected to lead to similar future BGLs. Find the most similar situation at time t in the past, use its BGL(t + 60) as an additional feature: RNNs can theoretically learn long-term dependencies. In practice, hard to train to remember => use explicit memory. 48
49 Attention Model for Time Series Prediction G 1 G 2 G 2 G t f(h 0,U 1 ) f(h 1,U 2 ) f(h t-1,u t ) H 1 H 2 H 2 H t U 1 U 2 U 2 U t 49
50 Attention Model for Time Series Prediction u = argmax a H +, H ) )*+ a(h t,h 1 ) a(h t,h 2 ) Use a H +, H ) and G u+60 as features. f(h 0,U 1 ) f(h 1,U 2 ) a(h t,h 3 ) f(h t-1,u t ) H 1 H 2 H 2 H t U 1 U 2 U 2 U t 50
51 Attention Model for Time Series Prediction Use a two-hidden layer fully connected network to compute attention: a H +, H ) =σ(w 2 relu W 7 H + ; H ) + b2 + b1) Use a H +, H ) and G u+60 as input features for the linear output layer, together with H t, to predict G t or G t
52 Evaluation Datasets Diabetes simulators: AIDA, from Generated 20 individual patient profiles: Each patient has 600 independent days. BGLs come every 15 minutes. University of Viginia (Uva) from tegvirginia.com: Generated 5 patient profiles: Each patient has 90 consecutive days. BGLs come every 1 minute (use every 5 minute). Real patient data: 5 patients, each with 70 consecutive days. BGLs measured every 5 minutes. 52
53 AIDA Sample 53
54 Uva Sample 54
55 Experimental Results for 60 Minute Horizon Points with what-if events are kept: System AIDA UVa Real LSTM LSTM+Mem Marginal, but statistically significant (over 12 runs). Points with what-if events are removed: System AIDA UVa Real LSTM LSTM+Mem
56 Outline 1. BGL prediction using manually engineered physiological models: Physiological Equations + Kalman filtering + SVR. 2. BGL prediction using trained physiological models. RNNs with LSTM units. 3. Attention models for time series prediction. 4. From physiological models to automated BGL control. 56
57 Future Work: Automated BGL Control Pseudo-Inverse Physiological Model - Patient = Real Physiological Model η is desired BGL. η is actual BGL. μ is actual insulin delivered. Based on Figure from and discussion with Dr. Jim Zhu. μ is what-if insulin computed based on the physiological model. μb is insulin correction computed by the stabilizing controller, designed based on the physio model. 57
Using LSTMs to Learn Physiological Models of Blood Glucose Behavior
Using LSTMs to Learn Physiological Models of Blood Glucose Behavior Sadegh Mirshekarian 1, Razvan Bunescu 1, Cindy Marling 1, and Frank Schwartz 2 Abstract For people with type 1 diabetes, good blood glucose
More informationPredicting Blood Glucose with an LSTM and Bi-LSTM Based Deep Neural Network
Predicting Blood Glucose with an LSTM and Bi-LSTM Based Deep Neural Network Qingnan Sun, Marko V. Jankovic, Lia Bally, Stavroula G. Mougiakakou, Member IEEE Abstract A deep learning network was used to
More informationDilated Recurrent Neural Network for Short-Time Prediction of Glucose Concentration
Dilated Recurrent Neural Network for Short-Time Prediction of Glucose Concentration Jianwei Chen, Kezhi Li, Pau Herrero, Taiyu Zhu, Pantelis Georgiou Department of Electronic and Electrical Engineering,
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationToward Plug and Play Medical Cyber-Physical Systems (Part 2)
Toward Plug and Play Medical Cyber-Physical Systems (Part 2) Insup Lee PRECISE Center School of Engineering and Applied Science University of Pennsylvania EMSIG Autumn School Copenhagen, Denmark November
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationTHE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE
THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE Indicated for type 1 patients 14 and over. Prescription required. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it
More informationOutline. Model Development GLUCOSIM. Conventional Feedback and Model-Based Control of Blood Glucose Level in Type-I Diabetes Mellitus
Conventional Feedback and Model-Based Control of Blood Glucose Level in Type-I Diabetes Mellitus Barış Ağar, Gülnur Birol*, Ali Çınar Department of Chemical and Environmental Engineering Illinois Institute
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationWHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?
Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationGlucose Concentration Simulation for Closed-Loop Treatment in Type 1 Diabetes
American Society for Engineering Education (ASEE), Northeast Section Annual Conference, April 27-28, 208 Glucose Concentration Simulation for Closed-Loop Treatment in Type Diabetes Marilyn Urrea, Nora
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationAmbulatory Artificial Pancreas Platform (AAPP) User Manual
Ambulatory Artificial Pancreas Platform (AAPP) User Manual Welcome to the Artificial Pancreas User Manual. This manual is intended to teach you how to use the system in your clinical trial. If questions
More informationFine-tuning of The Dose of Insulin Pump
Fine-tuning of The Dose of Insulin Pump The manual does not guarantee specific individual or specific applicability of the environment, there is no express or implied warranties. Contents of this manual
More informationUsing the Bolus Wizard Calculator
9501179-011 Using the Bolus Wizard Calculator Objective Describe the features and benefits of the Bolus Wizard Calculator Key Points The Bolus Wizard: Estimates high blood glucose corrections using the
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationPhysical Activity/Exercise Prescription with Diabetes
Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationAn event-based point of view on the control of insulin-dependent diabetes
An event-based point of view on the control of insulin-dependent diabetes Brigitte Bidégaray-Fesquet Laboratoire Jean Kuntzmann Univ. Grenoble Alpes, France Réunion e-baccuss September 4th 20 Réunion e-baccuss,
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationRELEASED. first steps. Icon Icon name What it means
Icon Icon name What it means Connection The connection icon appears green when the Sensor feature is on and your transmitter is successfully communicating with your pump. The connection icon appears gray
More informationVIRTUAL PATIENTS DERIVED FROM THE
VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationWhy (and how) I built an artificial
Why (and how) I built an artificial pancreas This is not about how cool it is (though it is!) to text my pancreas. This is about what s possible when you & I decide to stop waiting. I m not: An Engineer
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationDiabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018
Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018 Pumps & Sensors & Meters, Oh My! A Tale of Two Meters Technology for glucometers
More informationMachine Learning Experiments with Noninvasive Sensors for Hypoglycemia Detection
Machine Learning Experiments with Noninvasive Sensors for Hypoglycemia Detection Cindy Marling 1, Lijie Xia 1, Razvan Bunescu 1 and Frank Schwartz 2 1 School of Electrical Engineering and Computer Science,
More informationC o n n e c t e d I n s u l i n D e l i v e r y S y s t e m
Technology Innovation Alert C o n n e c t e d I n s u l i n D e l i v e r y S y s t e m 6 July 12 July, 2018 1 4 0 0 Start ups Companies Universities Individuals Interesting Innovation Compliance with
More informationGLOOKO DREAMED FOR ANDROID USER GUIDE
GLOOKO DREAMED FOR ANDROID USER GUIDE November 2018 IFU-0017 02 TABLE OF CONTENTS TABLE OF CONTENTS GENERAL INFORMATION... 2 Product Description... 2 Glooko Intended Use... 2 Dreamed Intended Use... 2
More informationFood Intake Detection from Inertial Sensors using LSTM Networks
Food Intake Detection from Inertial Sensors using LSTM Networks Kyritsis Konstantinos Diou Christos Delopoulos Anastasios Multimedia Understanding Group Information Processing Laboratory Dpt. Electrical
More informationAnomaly Detection in the Artificial Pancreas
Anomaly Detection in the Artificial Pancreas Avila L., Martínez E. INGAR (CONICET-UTN) Abstract The integration of subcutaneous sensing and insulin delivery technologies with novel control strategies has
More informationBenchmark Machine Learning Approaches with Classical Time Series Approaches on the Blood Glucose Level Prediction Challenge
Benchmark Machine Learning Approaches with Classical Time Series Approaches on the Blood Glucose Level Prediction Challenge Jinyu Xie 1, Qian Wang 2, 1 Mathworks, Inc. 2 The Pennsylvania State University
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationBLOOD GLUCOSE PREDICTION MODELS FOR PERSONALIZED DIABETES MANAGEMENT
BLOOD GLUCOSE PREDICTION MODELS FOR PERSONALIZED DIABETES MANAGEMENT A Thesis Submitted to the Graduate Faculty of the North Dakota State University of Agriculture and Applied Science By Warnakulasuriya
More informationExercise Prescription in Type 1 Diabetes
Exercise Prescription in Type 1 Diabetes Michael Riddell, PhD Professor, Muscle Health Research Centre and School of Kinesiology & Health Science, York University Senior Scientist, LMC Diabetes & Endocrinology,
More informationTechnology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE
Technology for Diabetes: 101 Basic Rules of the Road Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE Quick Pump Facts! o Constant insulin supply o Pager-sized mini-computer worn
More informationFayrouz Allam Tabbin Institute for Metallurgical Studies, Helwan, Egypt
I.J. Intelligent Systems and Applications, 2012, 10, 58-71 Published Online September 2012 in MECS (http://www.mecs -press.org/) DOI: 10.5815/ijisa.2012.10.07 Evaluation of Using a Recurrent Neural Network
More informationProceedings of the 5th WSEAS International Conference on Telecommunications and Informatics, Istanbul, Turkey, May 27-29, 2006 (pp )
A Predictive Control Approach For Nonlinear Systems MALIK F. ALAMAIREH, MOHAMMAD R. HASSAN Department of Computer Science Amman University Assalt 19112 P. O. Box 5043 JORDAN Abstract: - The theory of artificial
More informationApplying STPA to the Artificial Pancreas for People with Type 1 Diabetes
Applying STPA to the Artificial Pancreas for People with Type 1 Diabetes Lane Desborough Product Strategist Medtronic Diabetes Northridge, California Type 1 Diabetes Artificial Pancreas Challenges Applying
More informationIJESRT INTERNATIONAL JOURNAL OF ENGINEERING SCIENCES & RESEARCH TECHNOLOGY PID CONTROLLER FOR BLOOD GLUCOSE CONTROL Ajmal M M *, C R Srinivasan *
[Ajmal* et al., 6(3): March, 217] Impact Factor: 4.116 IC Value: 3. IJESRT INTERNATIONAL JOURNAL OF ENGINEERING SCIENCES & RESEARCH TECHNOLOGY PID CONTROLLER FOR BLOOD GLUCOSE CONTROL Ajmal M M *, C R
More information7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants
Dana Lewis Founder, #OpenAPS Seattle, WA Disclosure to Participants Notice of Requirements For Successful Completion Please refer to learning goals and objectives Learners must attend the full activity
More informationEnergy balance. Changing rate of energy expenditure
Energy balance Changing rate of energy expenditure 2 Physical activity and exercise Physical activity Occupational activity Physical Activity Exercise (business, work) Leisure activity (Recreational activities,
More informationModeling Type One Diabetes with a Linear Response Function Based Model
Modeling Type One Diabetes with a Linear Response Function Based Model Physics Honors Thesis Matthew Bauerle Advisor: Prof. Roman Vershynin Physics Honors Thesis July 29, 2016 Abstract Type one diabetes
More informationDiabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013
Diabetes through my eyes Rick Mauseth, M.D. W.A.D.E. April 2013 Ant hills Total Available Glucose utilized Two drops of urine in test tube Add 10 drops of water Added tablet Foamed and got hot Compared
More informationPOPULATION TRACKER - DREAMED USER GUIDE
POPULATION TRACKER - DREAMED USER GUIDE November 2018 IFU-0011 05 TABLE OF CONTENTS TABLE OF CONTENTS GENERAL INFORMATION... 1 Product Description... 1 Glooko Intended Use... 1 DreaMed Intended Use...
More informationCGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117
CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current
More informationDiabetes Mellitus. Disclaimer. Multimedia Health Education
Disclaimer This movie is an educational resource only and should not be used to manage Diabetes or blood sugar control.all decisions about management of diabetes must be made in conjunction with your Physician
More informationType 1 Diabetes: Managing a Critical Ratio Name
Open the TI-Nspire document Type_1_Diabetes_ Managing_a_critical_ratio.tns. Meet Chelcie. Chelcie is a 22 year old nursing student in the last semester of her clinical rotations at a Sanford Hospital.
More information1. What s the point of a network the case for research? 2. How to use CSII effectively
1. What s the point of a network the case for research? 2. How to use CSII effectively John Pickup King s College London Faculty of Medicine Guy s Hospital, London What should an insulin pump network do?
More informationREPORT INTERPRETATION
REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,
More informationA Virtual Glucose Homeostasis Model for Verification, Simulation and Clinical Trials
A Virtual Glucose Homeostasis Model for Verification, Simulation and Clinical Trials Neeraj Kumar Singh INPT-ENSEEIHT/IRIT University of Toulouse, France September 14, 2016 Neeraj Kumar Singh A Perspective
More informationFirst steps for success.
First steps for success. Getting to know continuous glucose monitoring (CGM). The Animas Vibe System is approved for persons age 2 and older. Important Safety Information The Animas Vibe Insulin Pump and
More informationUniversity College Hospital. Managing meals high in protein and/or fat a guide for Omnipod pump users
University College Hospital Managing meals high in protein and/or fat a guide for Omnipod pump users Children and Young people s diabetes service This information is based on the research and experience
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationSugarMate: Non-intrusive Blood Glucose Monitoring with Smartphones
SugarMate: Non-intrusive Blood Glucose Monitoring with Smartphones WEIXI GU, Tsinghua-Berkeley Shenzhen Institute, Tsinghua University YUXUN ZHOU, EECS, University of California, Berkeley ZIMU ZHOU, Computer
More informationActive Insulin Infusion Using Fuzzy-Based Closed-loop Control
Active Insulin Infusion Using Fuzzy-Based Closed-loop Control Sh. Yasini, M. B. Naghibi-Sistani, A. Karimpour Department of Electrical Engineering, Ferdowsi University of Mashhad, Mashhad, Iran E-mail:
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationChapter 37: Exercise Prescription in Patients with Diabetes
Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationUnderstanding the CareLink TM Therapy Management Dashboard Report
3 2 1 5 6 7 4 1 This is a great place to start recognizing trends. In this example you may see plenty of events that result in a low glucose trend. A low glucose is identified as a value less than 70mg/dL.
More informationAchieving Open-loop Insulin Delivery using ITM Designed for T1DM Patients
I. J. Computer Network and Information Security, 2012, 1, 52-58 Published Online February 2012 in MECS (http://www.mecs-press.org/) DOI: 10.5815/ijcnis.2012.01.07 Achieving Open-loop Insulin Delivery using
More informationParadigm/Guardian CGM Screens. CareLink Online Reports. Make Your Own Jackson Pollack. CGM by Jackson Pollack. How To Read CGM Screens/Reports
CGM by Jackson Pollack One Pollack sold for $140 million in 1996! Make Your Own Jackson Pollack How To Read CGM Screens/Reports For only $1,000! Paradigm/Guardian CGM Screens On-Screen Reports 3 / 6 /
More informationNow you know. InPen MOBILE APP. Healthcare Provider INSTRUCTIONS FOR USE. CompanionMedical.com Companion Medical, Inc.
InPen MOBILE APP Healthcare Provider INSTRUCTIONS FOR USE 2017 Companion Medical, Inc. LBL-00235-AC TABLE OF CONTENTS Introduction...3 InPen Mobile App...3 Intended Use...3 Indications for Use...3 Contraindications...3
More informationInsulin Pump Therapy. WakeMed Children s Endocrinology & Diabetes WakeMed Health & Hospitals Version 1.3, rev 5/21/13 MP
Insulin Pump Therapy WakeMed Children s Endocrinology & Diabetes Overview What is an insulin pump? What are the advantages and disadvantages of an insulin pump? Lifestyle Changes Food Management Exercise
More informationLive life, less complicated. InPen MOBILE APP. Healthcare Provider INSTRUCTIONS FOR USE. CompanionMedical.com
InPen MOBILE APP Healthcare Provider INSTRUCTIONS FOR USE TABLE OF CONTENTS Introduction...3 InPen Mobile App...3 Intended Use...3 Indications for Use...3 Contraindications...3 Start Orders...4 General
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationUniversity College Hospital. Blood glucose and HbA 1 c targets
University College Hospital Blood glucose and HbA 1 c targets Children & Young People s Diabetes Service The diabetes team at UCLH aims to help every child and young person with Type 1 Diabetes to safely
More informationPROBLEM DETECTION FOR SITUATION ASSESSMENT IN CASE-BASED REASONING FOR DIABETES MANAGEMENT. A thesis presented to. the faculty of
PROBLEM DETECTION FOR SITUATION ASSESSMENT IN CASE-BASED REASONING FOR DIABETES MANAGEMENT A thesis presented to the faculty of the Russ College of Engineering and Technology In partial fulfillment of
More informationMonitoring of Blood Glucose Level
University of Zagreb Faculty of Electrical Engineering and Computing Biomedical instrumentation Monitoring of Blood Glucose Level Biomedical instrumentation 1/17 Outline Introduction Principles of Blood
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationStandard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8
Standard Operating Procedure 11 Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Date Version Issue Review Contact Approved Date Date Person October 2013 9 October 2013 March
More informationIndian Pharmaceutical Association Indian Pharmaceutical Association
55 th National Pharmacy Week November 20 th to 26 th 2016 Theme Pharmacists for a Healthy India: Role in Prevention and Management of Diabetes Indian Pharmaceutical Association www.ipapharma.org Indian
More informationGuide to Flexible Insulin Therapy for Families
Guide to Flexible Insulin Therapy for Families Purpose of Guide This guide is for people with type one diabetes on flexible insulin therapy. The purpose of this information is to explain flexible insulin
More informationPROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY
PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY Situations Requiring Special Consideration and Resource Documents Second Edition MiniMed 67G System Medical Education TABLE OF CONTENTS A PROTOCOL FOR HYBRID
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationRELEASED. Clearing your active insulin
To clear all your settings: 1. Make sure the pump is not connected to your body. 2. Go to the Manage Settings screen. Menu > Utilities > Manage Settings 3. Simultaneously press and hold and until the Manage
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationBlood glucose Meter Roche USA V6/ PMS 287 Proof Print Number 209 Advanced Owner s Booklet
This file may not print or view at 100%. Die lines and color breaks do not print. Roche USA 50841 V6/1 06434258002 Black Proof Print Number 209 06434258002-0512 Roche USA 50841 V6/2 06434258002 Cyan Proof
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationINTERNATIONAL JOURNAL OF PURE AND APPLIED RESEARCH IN ENGINEERING AND TECHNOLOGY
INTERNATIONAL JOURNAL OF PURE AND APPLIED RESEARCH IN ENGINEERING AND TECHNOLOGY A PATH FOR HORIZING YOUR INNOVATIVE WORK A SLIDING MODE CONTROL ALGORITHM FOR ARTIFICIAL PANCREAS NIRLIPTA RANJAN MOHANTY
More informationFigure 2.1: Glucose meter
CHAPTER TWO: MONITORING TECHNOLOGIES 2.1 Introduction Glucose monitoring is a method of self-testing glucose (blood sugar) levels for the management of diabetes. Traditionally, it involves pricking the
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationWelcome to CareLink Pro
Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients
More informationCALIPSO Project. an innovative approach to insulin therapy management
CALIPSO Project an innovative approach to insulin therapy management Preface Our project Preliminary business plan Project Team Calipso Project 2015 Why it should be so hard for diabetics to manage their
More informationCurrent Glucometers. Junior s s Glucose Log. All have advantages and disadvantages Answer 2
Diabetes Dilemmas: Using Technology To Solve Clinical Conundrums Stephen E. Gitelman, MD UCSF A teenager with type 1 diabetes for 5 years comes into your office for a follow- up visit. You want to review
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationChallenges in Developing Learning Algorithms to Personalize mhealth Treatments
Challenges in Developing Learning Algorithms to Personalize mhealth Treatments JOOLHEALTH Bar-Fit Susan A Murphy 01.16.18 HeartSteps SARA Sense 2 Stop Continually Learning Mobile Health Intervention 1)
More informationConvolutional and LSTM Neural Networks
Convolutional and LSTM Neural Networks Vanessa Jurtz January 12, 2016 Contents Neural networks and GPUs Lasagne Peptide binding to MHC class II molecules Convolutional Neural Networks (CNN) Recurrent and
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More information